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Article
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Matthew J. Jasinski,1 Mark A. Lumley,1 Sandeep Soman,2 Jerry Yee,2 and Mark W. Ketterer3

1

Department of
Psychology, Wayne
State University,
Detroit, Michigan; and
Departments of
2
Nephrology and
3
Psychiatry, Henry
Ford Hospital, Henry
Ford Health System,
Detroit, Michigan

Abstract
Background and objectives The US Centers for Medicare and Medicaid Services have mandated reducing
early (30-day) hospital readmissions to improve patient care and reduce costs. Patients with ESKD have
elevated early readmission rates, due in part to complex medical regimens but also cognitive impairment,
literacy difﬁculties, low social support, and mood problems. We developed a brief family consultation
intervention to address these risk factors and tested whether it would reduce early readmissions.
Design, setting, participants, & measurements One hundred twenty hospitalized adults with ESKD (mean age=58
years; 50% men; 86% black, 14% white) were recruited from an urban, inpatient nephrology unit. Patients were
randomized to the family consultation (n=60) or treatment-as-usual control (n=60) condition. Family consultations, conducted before discharge at bedside or via telephone, educated the family about the patient’s cognitive and
behavioral risk factors for readmission, particularly cognitive impairment, and how to compensate for them.
Blinded medical record reviews were conducted 30 days later to determine readmission status (primary outcome)
and any hospital return visit (readmission, emergency department, or observation; secondary outcome). Logistic
regressions tested the effects of the consultation versus control on these outcomes.
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Results Primary analyses were intent-to-treat. The risk of a 30-day readmission after family consultation
(n=12, 20%) was 0.54 compared with treatment-as-usual controls (n=19, 32%), although this effect was not
statistically signiﬁcant (odds ratio, 0.54; 95% conﬁdence interval, 0.23 to 1.24; P=0.15). A similar magnitude,
nonsigniﬁcant result was observed for any 30-day hospital return visit: family consultation (n=19, 32%)
versus controls (n=28, 47%; odds ratio, 0.53; 95% conﬁdence interval, 0.25 to 1.1; P=0.09). Per protocol analyses
(excluding three patients who did not receive the assigned consultation) revealed similar results.
Conclusions A brief consultation with family members about the patient’s cognitive and psychosocial risk factors
had no signiﬁcant effect on 30-day hospital readmission in patients with ESKD.
Clin J Am Soc Nephrol 13: 850–857, 2018. doi: https://doi.org/10.2215/CJN.08450817

Introduction

The pursuit of “high value” health care, deﬁned as
the best possible outcomes at lowest possible costs
(1), is one goal of the US Patient Protection and
Affordable Care Act. One speciﬁc mechanism to
achieve this goal has been the reduction of avoidable
early hospital readmissions for discharged inpatients
(2). Early readmissions—admissions within 30 days
of discharge—reﬂect recurrent medical crises of sufﬁcient severity to warrant a hospitalization, although
less acute medical crises are also of concern and are
often managed in the emergency department or observation units (3).
Patients with ESKD have the highest 30-day readmission rates of all patients in the US Medicare/
Medicaid population, averaging .30% across hospitals nationwide (2,3). Such readmissions are likely
850
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related to a high disease burden and driven by patient
nonadherence (4); many patients with ESKD do not
adhere to diet, ﬂuid-intake, and medication regimens
(5). Yet, uncoordinated or inadequate advanced care
or discharge planning also contributes to early readmissions (6,7).
Behavioral factors driving readmission have rarely
been examined (8), although research suggests that
cognitive impairment, identiﬁed by clinical bedside
examination, predicts early readmissions (9,10). In
fact, cognitive impairment has been found to prospectively predict hospital admission and mortality in
chronically ill patients (9,11–13), a result even more
likely to occur when attending physicians are unaware of the patient’s cognitive limitations (14). Indeed, medical providers and family members are poor
at recognizing cognitive impairment among patients,
www.cjasn.org Vol 13 June, 2018
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particularly when only mild or moderate in severity (15–
17). Additional factors that likely contribute to early readmission are low health literacy, poor patient-physician
relationships, psychiatric and substance abuse history, and
limited social support (5). Together, these risk factors likely
cause individuals to ﬂounder with the complexities of their
self-care at home, especially in the absence of compensatory
assistance (4,18,19).
Involving family members or support people in the care
of chronically ill patients is generally beneﬁcial and is
associated with better adherence (20–24). We anticipated
that an intervention to educate family members about the
patient’s risk factors and to mobilize reliable social support
would reduce some of the risk of cognitive impairment,
literacy problems, and mood disturbances, thereby reducing early readmissions in patients with ESKD (10,25–27). In
another pilot study, we found that a brief family consultation was associated with a reduction in readmissions
among patients with congestive heart failure (26).
In the current trial, we reﬁned the family consultation
developed and piloted earlier (26) and tested it in a randomized, controlled trial among patients with ESKD. Our
prespeciﬁed primary outcome and endpoint was the presence or absence of a hospital readmission within 30 days
of discharge. We also analyzed the presence of any unplanned early hospital return visit, including not only
readmissions but also observation status and emergency
department visits; although the latter two are not yet
targeted by the Affordable Care Act, they represent the
larger set of clinically relevant negative outcomes. We tested
the hypothesis that the family consultation would reduce
30-day readmissions (primary outcome) and unplanned
early hospital visits (secondary outcome), compared with
treatment as usual (i.e., no added family consultation). We
also included a secondary endpoint (6-month follow-up) to
determine the duration of any effects of the family
consultation.

Methods
Participants and Recruitment
Participants were adult patients (aged 18 or older) diagnosed with ESKD who were hospitalized on the nephrology unit at Henry Ford Hospital in Detroit, Michigan.
Inclusion criteria were a current admission to the unit and
willingness to contact a family member or friend, who was
expected to be available and willing to meet with the consultant if the patient was randomized into the experimental
condition. To maximize generalizability, exclusion criteria
were few: delirium, inability to speak English, and unavailability or discharge before recruitment and informed
consent. We included not only patients with cognitive
impairment, but also those with no evidence of cognitive
impairment, because the latter often have other risk factors
for readmission (e.g., low support, literacy problems) and
remain at risk for future cognitive impairment.
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secondary (6-month) outcome assessment completed in
October of 2016. The study protocol was approved by
the hospital’s institutional review board and adhered to
the ethical principles in the Declaration of Helsinki. The
randomization scheme was created before recruitment
began by an independent research assistant using a computer program (randomization.com). Randomization
in a 1:1 allocation ratio was stratiﬁed by patient sex (male
or female) and conducted in randomized blocks of six
or eight; assignments were placed in sealed, opaque envelopes. Figure 1 presents the ﬂow of patients through the
trial.
Patients were approached at bedside on the nephrology
unit. Those who met study criteria were informed about
the trial, and written consent was obtained. Patients then
completed several questionnaires, which informed the
subsequent family consultation (if assigned). Given concerns about literacy in this population, questionnaire items
were read aloud by the researcher to assure the patient’s
understanding. After the assessment, the researcher unsealed the envelope to determine the assigned condition;
patients and researcher were blind to condition assignment
before this point. Patients were remunerated for participating in the initial assessment.
Patient Descriptive Measures
Cognitive impairment and educational attainment were
assessed with the Montreal Cognitive Assessment (28),
which is a brief (approximately 10-minute), easily administered and scored screening instrument to detect signs of
cognitive impairment among patients in medical settings.
The measure assesses executive function, immediate memory, language, abstraction, short-term memory, and orientation, with a correction for education level. Scores ,23 are
considered in the cognitively impaired range.
Health literacy was assessed with the Rapid Estimate of
Health Literacy in Medicine-Short Form (REALM-SF) (29),
which is a brief (approximately 2-minute) screening instrument for use in medical settings to assess patients’
reading level. A score ,7 represents reading ability below
the ninth grade level.
Social support was assessed with three items from the
Diabetes Social Support Questionnaire–Family Version
(30), and two items from the Modiﬁed Scale of Social
Support–5 (31).
Treatment adherence was assessed with the four-item
Immunosuppressant Therapy Adherence Scale, with wording changed to refer to patients with ESKD (32). A ﬁfth item
“How often did you miss your planned dialysis sessions?”
was added.
Depression was assessed using the Patient Health Questionnaire–8 (33).
Anxiety was assessed using the Generalized Anxiety
Disorder 7-Item Scale (34).

Experimental Conditions
Procedure
This trial was registered at clinicaltrials.gov
(NCT02504021) before recruitment, which occurred from
July of 2015 to March of 2016, with primary (30-day)
outcome assessment completed in May of 2016, and

Family Consultation Condition
The model underlying the intervention posits that it is
beneﬁcial to provide patients and their families with plain
language, nonthreatening information about the patient’s
unique psychosocial risk factors for health problems and to
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Figure 1. | Consolidated standards of reporting trials (CONSORT) flowchart displaying recruitment, randomization, and participation.

encourage the family to support the patient’s adaptive
health behaviors. The consultation consisted of one relatively brief session conducted by a male clinical psychology
predoctoral intern, supervised by a doctoral psychologist.
To maintain trial integrity, the consultant worked independently from the rest of the health care team on the unit.

The family consultation was conducted while the patient
was in hospital, as soon as possible after the background
assessment and randomization. If the family member or
support person selected by the patient was present or could
be readily scheduled to come to the hospital, the consultation was conducted at the bedside with both the patient
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and family member/support person. However, in-person
family meetings were sometimes not feasible, so to maximize participation, some family consultations occurred by
telephone. In such cases the consultation was conducted
with the family member over the phone, and patients were
subsequently briefed about the content of the discussion.
The family consultation had several components. The
consultant: (1) introduced himself and informed the family
member and patient that the health care team was working to
improve postdischarge care by communicating better with
the patient’s support people; (2) built rapport by providing
empathy regarding the burden of managing ESKD; (3)
reviewed patient and family understanding of events that
caused the hospital admission; (4) explained cognitive
impairment (as “forgetfulness”) and educated the patient
and family about of the level of cognitive impairment that
the patient was experiencing by discussing the results of the
initial cognitive assessment; (5) discussed ways for the
support person to assist the patient with his or her medication adherence, even when the patient displayed no overt
signs of cognitive impairment; (6) tailored the consultation to
each patient by including information about other risk factors
identiﬁed in the initial assessment (i.e., health literacy, social
support, and adherence); and (7) used motivational interviewing techniques, as indicated, such as asking permission
to make recommendations, and reﬂecting ambivalence (35)
over patient-reported treatment adherence.
Control Condition
After the initial assessment, control patients engaged
only in their medical treatment as usual. No family consultations were conducted.
Outcome Measures: Early Readmissions and Hospital Visits
Two outcome variables were extracted from the electronic medical record of each patient. The prespeciﬁed
primary outcome and endpoint was whether a patient was
readmitted as an inpatient within 30 days of discharge from
the index admission. This is the narrowly deﬁned Affordable Care Act metric with ﬁnancial penalties, which is used
by hospitals nationwide. This metric, however, misses
several additional problematic outcomes that fall short of
full readmission, which we observed early in the trial.
Thus, before outcome data collection, we deﬁned a secondary outcome: whether a patient had any unplanned
return hospital visit, deﬁned as an observation unit visit,
an emergency department visit, or an inpatient readmission within 30 days of discharge. All outcome data were
initially retrieved by the consultant, and then independently retrieved by a senior staff member blinded to experimental condition. Complete agreement between the
two coders was .98%; the few differences were resolved
by consensus. After 6 months, a blinded reviewer again
classiﬁed patients as to whether they had had a readmission or any unplanned return hospital visit during the
prior 6 months.
Statistical Analyses
An initial power analysis, conducted with G*Power
3.1.9.2, yielded the sample size needed to obtain power
of 0.80, given an estimated medium effect size (w=0.3)
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difference between the two conditions on the primary
outcome (presence or absence of an early readmission), in a
232 contingency table with a=0.05. A minimum of 88
patients was indicated; however, we recruited beyond that
number to increase our power. Analyses of the effects of the
family consultation versus control on the primary and
secondary outcomes at the 30-day and 6-month endpoints
were conducted with logistic regressions. Primary analyses
were conducted on the full, intent-to-treat sample; secondary “per protocol” analyses excluded three patients who
did not receive the assigned family consultation (described
below). All analyses were conducted two-tailed using an a
of 0.05. Primary analyses were conducted with no covariates, although we ran a sensitivity analysis, adjusting the
logistic model for variables that seemed to be imbalanced at
baseline. For effect sizes, we calculated the odds ratio (OR;
,1.0 indicates reduced readmissions/unplanned return
visits for family consultation relative to controls) and 95%
conﬁdence interval (95% CI). For signiﬁcant effects, we also
calculated the number needed to treat; that is, the number
of patients who would need the family consultation to prevent one negative outcome (an early readmission or unplanned hospital visit).

Results
Sample Descriptives
As shown in Figure 1, we screened 171 patients, and 156
(92%) were eligible for inclusion. Of these, 120 (77%) were
randomized. Sociodemographic and medical history data
for the full sample and each condition separately are
presented in Table 1. The overall sample was half men and
half women, had a mean age of 58 years (SD=14; range=
24–88), was predominantly black (86%), and less than half
(43%) had education beyond high school. Patient literacy
averaged between the seventh and eighth grade level. In
addition to ESKD, most patients had multiple medical
comorbidities.
The family consultation was conducted as planned for 57
of the 60 patients randomized to the consultation condition;
family consultations did not occur for three patients for
whom the consultant was unable to reach any support
person, even after three attempted telephone calls. The 57
consultations were relatively brief, averaging about 8
minutes (SD=5.0 minutes, range: 2–30 minutes); 23 consultations (40%) were conducted with the family at bedside, and the rest (60%) were conducted over the telephone.
Consultations involved a variety of different support people: 17 (30%) spouses, 12 (21%) children, ten (16%) parents,
six (11%) siblings, six (11%) multiple people, and six (11%)
nonrelatives.
Testing the Superiority of Family Consultation to Treatment
as Usual
As shown in the top half of Table 2, under intent-to-treat
analyses, the two conditions did not differ signiﬁcantly
(P=0.15) on the prevalence of early readmission; the rate of
readmission in the consultation (n=12, 20%) was numerically lower than in the control condition (n=19, 32%), and
the risk or odds of early readmission after consultation
compared with control was 0.54 (95% CI, 0.23 to 1.24). A
similar magnitude, nonsigniﬁcant result was seen for the
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Table 1. Baseline characteristics of participants randomly assigned to family consultation or treatment as usual in a clinical trial of
patients with ESKD discharged from an urban hospital
Variable
Demographics
Age (M, SD)
Sex (male)
Sex (female)
Race (black)
Race (white)
Education.12th grade
Medical risk factors
Congestive heart failure
Smoking
Diabetes
Hypertension
COPD
BUN (M, SD)
Serum creatinine (M, SD)
Phosphorous (M, SD)
Number of medications (M, SD)
On hemodialysis
Type of vascular accessa
AVF
AVG
Catheter
Charlson Comorbidity (M, SD)
Behavioral risk factors
Psychiatric diagnosis
Psychiatric medication
Substance use history
Positive toxicology screen
Cognitive risk factors
Delirium
Positive head imaging
History of seizures
History of hypoxia
Dementia
Stroke history
Cognitive impairment (M, SD)
Initial assessment (M, SD)
Health literacy
Social support
Adherence
Depression
Anxiety

Total Sample
n=120

Family Consultation
n=60

Treatment as Usual
n=60

58 (14)
60 (50%)
60 (50%)
103 (86%)
17 (14%)
51 (42%)

58 (14)
30 (50%)
30 (50%)
51 (83%)
9 (15%)
24 (40%)

57 (15)
30 (50%)
30 (50%)
52 (86%)
8 (13%)
27 (45%)

58 (48%)
71 (59%)
74 (61%)
118 (98%)
22 (18%)
41 (23)
7.4 (3.7)
4.4 (1.7)
14.4 (5.9)
113 (94%)

28 (46%)
35 (58%)
42 (70%)
59 (99%)
10 (16%)
38 (19)
7.0 (3.3)
4.1 (1.5)
15.1 (5.9)
57 (95%)

30 (50%)
36 (60%)
32 (53%)
59 (99%)
12 (20%)
43 (26)
7.7 (3.9)
4.6 (1.9)
13.7 (5.9)
56 (93%)

45 (38%)
19 (16%)
47 (39%)
7.5 (3.1)

25 (42%)
7 (12%)
24 (40%)
7.6 (3.0)

20 (33%)
12 (20%)
23 (38%)
7.3 (3.3)

35 (29%)
30 (25%)
31 (25%)
11 (9%)

17 (28%)
14 (23%)
11 (18%)
4 (6%)

18 (30%)
16 (26%)
20 (33%)
7 (11%)

37 (30%)
61 (50%)
14 (11%)
19 (15%)
5 (4%)
10 (8%)
20. 5 (4.5)

17 (28%)
29 (48%)
6 (10%)
6 (10%)
2 (3%)
4 (6%)
20. 5 (4.8)

20 (33%)
32 (53%)
8 (13%)
13 (21%)
3 (5%)
6 (10%)
20. 4 (4.2)

5.5 (2.1)
2.9 (1.0)
2.4 (0.6)
6.8 (4.6)
5.3 (4.6)

5.1 (2.0)
2.9 (1.0)
2.4 (0.6)
6.9 (4.3)
5.2 (4.1)

5.4 (2.2)
2.9 (1.1)
2.4 (0.6)
6.7 (4.9)
5.2 (5.0)

Data are presented as n (%) and mean (M) standard deviation (SD) where applicable. COPD, chronic obstructive pulmonary disease;
AVF, arteriovenous ﬁstula; AVG, arteriovenous graft; tox, toxicology.
a
This information was missing from 11 patients.

occurrence of any early hospital return visit: family consultation condition (n=19, 32%), control condition (n=28,
47%; OR, 0.53; 95% CI, 0.25 to 1.11; P=0.09). At 6 months,
condition differences were much smaller, and family
consultation did not differ signiﬁcantly from control on
either the prevalence of readmission or any hospital return
visit.
Two of the three patients who did not get the family
consultation as assigned had an early readmission, and all
three of these patients had an early return visit. Per protocol
analyses that excluded these three patients revealed nonsigniﬁcant condition differences that were slightly larger
than noted under intent-to-treat analyses. As shown in the
bottom half of Table 2, the prevalence of early readmission
did not differ signiﬁcantly between the family consultation
condition (n=10, 18%) and the control condition (n=19,

32%; OR, 0.46; 95% CI, 0.19 to 1.10; P=0.08). Finally, the
family consultation condition had a signiﬁcantly lower
prevalence of any unplanned early hospital return visit
(n=16, 28%) than did the controls (n=28, 47%); the odds of
any return visit after family consultation compared with
control were 0.45 (95% CI, 0.21 to 0.96; P=0.04; number
needed to treat=6). Again, at 6 months, the condition
differences were negligible, and neither readmissions nor
unplanned return visits differed signiﬁcantly between
conditions.
Finally, we ran a sensitivity analysis on our primary outcome to test the effects of a possible imbalance between the
two conditions in several background factors: history of
diabetes, hypoxia, substance use history, and a positive
toxicology screen. Adjusting the logistic model simultaneously for these covariates indicated that the risk of early
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Table 2. Outcomes of a clinical trial comparing family consultation to treatment as usual among patients with ESKD discharged from an
urban hospital
Variable

Family Consultation

Treatment as Usual

Intent-to-treat analyses
30-d readmissiona
Yes
No
30-d any return visit
Yes
No
6-mo readmission
Yes
No
6-mo any return visit
Yes
No
Per-protocol analyses
30-d readmission
Yes
No
30-d any return visit
Yes
No
6-mo readmission
Yes
No
6-mo any return visit
Yes
No

(n=60)

(n=60)

12 (20.0%)
48 (80.0%)

19 (31.7%)
41 (68.3%)

19 (31.7%)
41 (68.3%)

28 (46.7%)
32 (53.3%)

38 (63.3%)
22 (36.7%)

39 (65.0%)
21 (35.0%)

45 (75.0%)
15 (25.0%)
(n=57)

48 (80.0%)
12 (20.0%)
(n=60)

10 (17.5%)
47 (82.5%)

19 (31.7%)
41 (68.3%)

16 (28.1%)
41 (71.9%)

28 (46.7%)
32 (53.3%)

35 (61.4%)
22 (38.6%)

39 (65.0%)
21 (35.0%)

42 (73.7%)
15 (25.0%)

48 (80.0%)
12 (20.0%)

OR

95% CI

P

0.54

0.23 to 1.24

0.15

0.53

0.25 to 1.11

0.09

0.93

0.44 to 1.96

0.85

0.75

0.32 to 1.77

0.51

0.46

0.19 to 1.10

0.08

0.45

0.21 to 0.96

0.04

0.86

0.40 to 1.82

0.69

0.70

0.30 to 1.66

0.42

Data are presented as n (%). OR, odds ratio; 95% CI, 95% conﬁdence interval.
a
Prespeciﬁed primary study outcome at the primary endpoint (30 d) in primary analyses (intent-to-treat). All other outcomes, endpoint,
and analyses are secondary.

readmission after consultation compared with control was
largely unchanged from the unadjusted model presented
above: the OR changed only from 0.54 to 0.55 (95% CI, 0.23
to 1.32), and the condition effect remained nonsigniﬁcant
(P=0.18).

Discussion
Patients with ESKD are at substantial risk for early
readmission, particularly due to cognitive impairment, low
health literacy, low social support, and subsequent nonadherence to medications and dialysis (9,10). This randomized controlled trial tested whether a brief behavioral
intervention among patients with ESKD—consulting
with the patient’s family members about the patient’s cognitive status and other risk factors and the need for better
adherence—could reduce early (30-day) hospital readmissions and, secondarily, any unplanned early return visit,
compared with treatment as usual (no family consultation).
The consultation yielded a small-to-medium effect that was
not statistically signiﬁcantly different than that observed
among controls.
Although our central focus was the effect of family consultation on readmissions and unplanned return visits, it
also is important to understand the mechanisms or processes
by which the consultation may achieve such beneﬁts. Unfortunately, we were unable to collect reliable data on
possible mechanisms after discharge, such as improvements in medication or dialysis adherence, family communication patterns, or reduced stress. Thus, we must rely

on our knowledge of the general literature, this population,
and some anecdotal observations to speculate about possible mechanisms.
We suspect that any reductions in early readmission or
unplanned return visits after a family consultation could
result from destigmatized education of the patient and family
regarding the complexities of managing ESKD and the
challenges that patients experience, particularly the existence
of cognitive impairment and its implications for adherence.
Many patients and family members in this trial remarked that
no one had ever explained to them that cognitive impairment
(i.e., “forgetfulness”) was common in patients with ESKD,
and that such impairment puts them at risk for missing
medications and dialysis treatments, resulting in further
hospital care. Research has noted problems in medication
adherence among cognitively impaired patients with congestive heart failure, and studies in other populations suggest
that family interventions can improve adherence (4,24,36).
Thus, the most plausible biobehavioral mechanism for
explaining why patients get readmitted is that they forget
to reﬁll prescriptions and take medications consistently, and/
or miss dialysis sessions. Therefore, we speculate that by
providing education to patients and families about the risk
that cognitive impairment plays in readmissions, one may
improve patients’ ability and willingness to utilize their
family to help with treatment adherence postdischarge.
The nonsigniﬁcant differences in 30-day readmissions
after family consultation found in this trial were completely
eliminated by 6-month follow-up. We think that a single,
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brief family consultation is unlikely to improve longer-term
outcomes. Families likely need additional consultations or
booster sessions to reinforce their motivation and maintain
the important behavioral or interpersonal changes they
make initially. Home health care may represent a feasible
opportunity to deliver these ongoing services.
This trial has several unique strengths. The consultation
was designed to maximize feasibility—being conducted
at bedside or via telephone—and did not rely on special
resources or involvement from other providers on the
nephrology unit. Also, very few patients were excluded,
and over three-quarters of eligible patients were randomized, thereby enhancing sample generalizability. Furthermore, the sample was one that is often viewed as
particularly high risk: urban, largely black patients, with
multiple social, economic, and behavioral risk factors. Given
these challenges, we believe that this intervention can be
implemented readily on other nephrology units and perhaps other hospitalized populations with chronic diseases
and high risk for readmission.
This trial has several limitations. First, most of the analyses
failed to reach statistical signiﬁcance, likely due to insufﬁcient
sample size. Our initial power analysis overestimated the
effect size; rather than medium in magnitude, our obtained
ORs are closer to a “small” effect (37), indicating the need
for a larger sample. Second, our results are limited to a
speciﬁc population and provider. Future trials should test the
consultation in different populations of people with ESKD
(including at-risk outpatients on hemodialysis) and with
more than a single consultant working independently from
the nephrology team. We predict that larger reductions in
early readmissions will be found when the family consultant
works closely with other providers on the unit. Third, initial
diagnoses, plans for follow up, and speciﬁc reasons for
readmission or return visits are complex and not well
delineated in medical records, which could bias the trial in
unknown ways. Also, it is possible that some patients were
readmitted to other hospitals of which we were unaware.
Fourth, as noted above, assessment of possible mechanisms
of change, particularly adherence to medications and dialysis
as well as family relations or communication, would clarify
how such a consultation might reduce early readmissions.
Fifth, baseline characteristics of family members (e.g., cognitive status and literacy), which could affect implementation
of the intervention, were not assessed. Finally, it is likely that
this intervention is most effective with subsets of patients,
such as those with a certain degree of cognitive impairment
or certain types of family relations, but our sample was not
large enough to reliably test such moderators. There is a
compelling argument for testing and disseminating interventions that assess cognitive impairment and other risk
factors and involve families in the care of patients. The results
of this trial, although not reaching statistical signiﬁcance, do
not completely exclude the value of greater involvement of
behavioral medicine in treatment and discharge planning.
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